Lanreotide Effective for Nonfunctional Neuroendocrine Cancers

Summary and Comment |
July 16, 2014

Lanreotide Effective for Nonfunctional Neuroendocrine Cancers

  1. David H. Ilson, MD, PhD

Progression-free survival was significantly improved with this long-acting somatostatin analogue versus placebo.

  1. David H. Ilson, MD, PhD

Neuroendocrine tumors arising in the pancreas or intestine, particularly low-grade tumors with a low proliferative index, often have a long natural history, even in the setting of metastatic disease. Standard therapy for tumors progressing on observation, or tumors producing functional polypeptides or vasoactive amines, is monthly injection with long-acting somatostatin analogues. Despite often good symptomatic control with this therapy, the antiproliferative effect of these agents is less well defined.

Investigators now report results of an international, multicenter, randomized, double-blind, placebo-controlled trial of the long-acting somatostatin analogue lanreotide in patients with low-grade, nonfunctional intestinal or pancreatic neuroendocrine tumors. A total of 204 patients received lanreotide (120 mg once every 28 days by deep subcutaneous injection) or placebo. Crossover to lanreotide was permitted at disease progression. Most patients were untreated (84%) and had not progressed within 3 to 6 months prior to study entry (95%–96%). Most tumor primaries were in the pancreas (42%–48%), and 28% to 32% had a Ki 67 proliferative index of 3%–10%.

Progression-free survival (PFS; the primary endpoint) was significantly improved with lanreotide versus placebo (not reached vs. 18 months; hazard ratio, 0.47; P<0.001). At 24 months, PFS was 65.1% with lanreotide versus 33.0% with placebo. Initial overall survival did not differ between arms, given the crossover design. Serious adverse events attributed to lanreotide were rare and included diarrhea and abdominal pain.


Lanreotide is now validated as an appropriate therapeutic option for nonfunctional neuroendocrine tumors. Although early therapy, even at recent diagnosis, is supported by this trial and the recently published PROMID trial using octreotide, it is unclear whether the current practice of initial observation and treatment with somatostatin analogue therapy only at clinical progression should change. The absence of a survival difference, and the PFS of 33% at 2 years on placebo, argue that initial observation and treatment only at progression remains a viable strategy for nonfunctional, low-grade neuroendocrine tumors.

Editor Disclosures at Time of Publication

  • Disclosures for David H. Ilson, MD, PhD at time of publication Consultant / Advisory board Amgen; Eli Lilly-Imclone Grant / Research support Bayer; Amgen; Bristol-Myers-Squibb


Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.